share_log

Novavax | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Novavax | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

诺瓦瓦克斯医药 | S-8：员工福利计划证券登记
美股sec公告 ·  08/08 16:21
Moomoo AI 已提取核心信息
On August 8, 2024, Novavax, Inc., a biotechnology company incorporated in Delaware and headquartered in Gaithersburg, Maryland, filed a Form S-8 registration statement with the Securities and Exchange Commission (SEC). This registration statement pertains to the issuance of additional shares under the company's employee benefit plans. Specifically, Novavax registered 1,810,264 additional shares of common stock for its Amended and Restated 2013 Employee Stock Purchase Plan and 6,500,000 additional shares for its Amended and Restated 2015 Stock Incentive Plan. The filing includes references to previous registration statements and incorporates by reference several of Novavax's financial documents, including annual and quarterly reports, as well as current reports and proxy statements. The registration statement also details the company's indemnification policies for directors and officers, and includes a list of exhibits related to the company's corporate governance documents.
On August 8, 2024, Novavax, Inc., a biotechnology company incorporated in Delaware and headquartered in Gaithersburg, Maryland, filed a Form S-8 registration statement with the Securities and Exchange Commission (SEC). This registration statement pertains to the issuance of additional shares under the company's employee benefit plans. Specifically, Novavax registered 1,810,264 additional shares of common stock for its Amended and Restated 2013 Employee Stock Purchase Plan and 6,500,000 additional shares for its Amended and Restated 2015 Stock Incentive Plan. The filing includes references to previous registration statements and incorporates by reference several of Novavax's financial documents, including annual and quarterly reports, as well as current reports and proxy statements. The registration statement also details the company's indemnification policies for directors and officers, and includes a list of exhibits related to the company's corporate governance documents.
2024年8月8日，生物技术公司Novavax，Inc.在特拉华州注册，总部设在马里兰州盖瑟斯堡，并向证券交易所（SEC）提交了S-8表格登记申报。此登记声明涉及公司在员工福利计划下发行的额外股份。具体而言，Novavax为其修订后的2013年员工股票购买计划注册了1810264股普通股，为修订后的2015年股票激励计划注册了6500000股额外股份。该申报包括对先前登记声明的引用，并通过引用几份Novavax的财务文件，包括年度和季度报告以及现报和代理声明。注册声明还详细说明了公司对董事和高管的赔付政策，并包括一份与公司公司治理文件有关的陈列清单。
2024年8月8日，生物技术公司Novavax，Inc.在特拉华州注册，总部设在马里兰州盖瑟斯堡，并向证券交易所（SEC）提交了S-8表格登记申报。此登记声明涉及公司在员工福利计划下发行的额外股份。具体而言，Novavax为其修订后的2013年员工股票购买计划注册了1810264股普通股，为修订后的2015年股票激励计划注册了6500000股额外股份。该申报包括对先前登记声明的引用，并通过引用几份Novavax的财务文件，包括年度和季度报告以及现报和代理声明。注册声明还详细说明了公司对董事和高管的赔付政策，并包括一份与公司公司治理文件有关的陈列清单。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息